Millennium Management
NMRA icon

Millennium Management’s Neumora Therapeutics NMRA Stock Holding History

Millennium Management’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-625,000
Closed -$6.63M – 6232
2024
Q4 		$6.63M Buy
+625,000
New +$7.49M ﹤0.01% 2567

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management's NMRA Position: Q1 2026 in Review

Millennium Management reduced its Neumora Therapeutics (NMRA) stake by 24% in Q1 2026, selling an estimated $2.23M and leaving 2,754,854 shares worth $5.37M. The position accounts for ﹤0.01% of the portfolio, ranked #2855.

Millennium Management first reported a position in NMRA in Q3 2023 and has held it in 8 quarters since. The position peaked at $6.47M in Q4 2025. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Millennium Management held 2,754,854 shares of Neumora Therapeutics worth $5.37M as of Q1 2026.
  • Millennium Management sold 861,660 Neumora Therapeutics shares in Q1 2026, an estimated $2.23M.
  • Neumora Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2855 holding.
  • Millennium Management first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 8 quarters since.
  • Millennium Management's Neumora Therapeutics position peaked at $6.47M in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.